BioMedNewsBreaks

FridayApr 25, 2025 9:51 am

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Grants Inducement Stock Option to New CEO Eric Poma

Calidi Biotherapeutics (NYSE American: CLDI) a clinical-stage biotechnology company advancing targeted antitumor virotherapies, announced the approval of an inducement non-qualified stock option grant to new Chief Executive Officer Eric Poma, Ph.D. The grant includes the option to purchase 726,412 shares at an exercise price of $0.469, the closing price of Calidi’s common stock on April 22, 2025. The options will vest over four years, with 25% vesting on April 22, 2026, and the remainder vesting in equal monthly installments through April 22, 2029, in accordance with Section 711 of the NYSE American LLC Company Guide.  To view the full press…

Continue Reading

FridayApr 25, 2025 9:00 am

BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Featured in Benzinga Video Highlighting 75% HyBryte™ Response Rate in FDA-Backed Skin Cancer Trial

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, is featured in a new Benzinga video detailing clinical progress for its lead candidate HyBryte™, which achieved a 75% response rate in a trial for cutaneous T-cell lymphoma (CTCL), a rare form of skin cancer. The trial is supported by funding from a U.S. Food and Drug Administration’s Orphan Products Development Grant and showcases HyBryte’s™ potential as a first-in-class, light-activated, non-invasive therapy. HyBryte™ is a first-in-class photodynamic therapy activated by safe visible light and has previously received Orphan Drug and Fast Track designations. Soligenix plans to continue advancing regulatory…

Continue Reading

ThursdayApr 24, 2025 9:20 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) and AccurKardia Partner to Advance Remote ECG Monitoring

HeartBeam (NASDAQ: BEAT), a medical technology firm innovating in personalized cardiac care, has announced a strategic collaboration with AccurKardia, a leader in ECG-based diagnostics. The partnership will integrate AccurKardia’s FDA-cleared ECG analysis software, AccurECG™, into HeartBeam’s compact, cable-free 3D ECG device. Designed to deliver 12-lead ECGs remotely, the device will be enhanced by automated arrhythmia assessments, aiming to accelerate diagnosis and improve access to cardiac care. The collaboration is expected to streamline HeartBeam’s product development while expanding the reach of remote cardiac monitoring solutions. To view the full press release, visit https://ibn.fm/KDDne About HeartBeam Inc. HeartBeam is a medical technology…

Continue Reading

WednesdayApr 23, 2025 10:38 am

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Appoints Eric Poma as CEO to Lead Next Phase of Clinical Growth

Calidi Biotherapeutics (NYSE American: CLDI) announced the appointment of Eric Poma, Ph.D., as Chief Executive Officer and member of its Board of Directors, effective Apr. 22. He succeeds Allan Camaisa, who will continue as a Board member. Dr. Poma, a veteran biotech leader, brings over 30 years of experience, including roles at Molecular Templates (NASDAQ: MTEM), where he raised over $250 million and secured strategic partnerships with Takeda, Vertex, and BMS. As Calidi advances its systemic virotherapy platform and prepares for a dose-escalation trial of CLD-201 in solid tumors, the leadership change is expected to support the company’s transition into…

Continue Reading

WednesdayApr 23, 2025 9:30 am

BioMedNewsBreaks — VERAXA Biotech AG and Voyager Acquisition Corp. (NASDAQ: VACH, “Voyager”) Announce $1.64 Billion Business Combination to Create Clinical-Stage Cancer Therapy Powerhouse 

VERAXA Biotech AG, a cancer therapy innovator, and proposed de-SPAC target of Voyager Acquisition Corp. (NASDAQ: VACH) announced a definitive agreement to merge in a transaction that would value the combined company at approximately $1.64 billion. Upon closing, VERAXA is expected to trade on NASDAQ under the ticker symbol “VERX.” The company is advancing a proprietary Bi-Targeted Antibody Cytotoxicity (“BiTAC”) platform for dual-marker cancer therapeutics, including bispecific ADCs and T cell engagers, with a pipeline featuring nine programs and an active Phase 1 trial in leukemia. VERAXA is backed by majority shareholders Xlife Sciences AG (SIX: XLS), EMBL and EMBLEM,…

Continue Reading

TuesdayApr 22, 2025 3:10 pm

BioMedNewsBreaks – BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) (FRA: 5LB), SpayVac-for-Wildlife Inc. Expand License Agreement

BioVaxys (CSE: BIOV) (OTCQB: BVAXF) (FRA: 5LB) and SpayVac-for-Wildlife announced an expansion of the fields of use in the current license agreement to include commercial aquaculture and the farm-raised fish market. With this expansion, SpayVac’s markets now include its no-booster fertility-control vaccines for aquaculture and overabundant feral/wild/invasive and select production and companion animals, which significantly increases its global revenue potential. “This presents a substantial addressable market for SpayVac’s contraceptive vaccines, which are being developed as an alternative to triploidy—a form of genetic manipulation commonly used in aquaculture to induce sterility,” said SpayVac-for-Wildlife CEO Thomas D’Orazio. “With only a single dose…

Continue Reading

TuesdayApr 22, 2025 9:30 am

BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) to Host Investor Webinar Highlighting Cancer Immunotherapy Pipeline

Calidi Biotherapeutics (NYSE American: CLDI) will host a live investor webinar on April 24, 2025, at 4:15 p.m. ET, featuring its new Chief Medical Officer, Dr. Guy Travis Clifton. The event will spotlight Calidi’s stem cell-based delivery platforms for oncolytic virus therapies, including the FDA-cleared CLD-201, which is advancing toward trials for solid tumors. Additional program updates will include CLD-400 for metastatic and lung cancer and CLD-101 for high-grade gliomas. A live Q&A will follow the presentation. To view the full press release, visit: https://ibn.fm/0we8c About Calidi Biotherapeutics Calidi Biotherapeutics specializes in proprietary technology that empowers the immune system to…

Continue Reading

TuesdayApr 22, 2025 9:00 am

BioMedNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Adjourns Special Meeting Due to Lack of Quorum

TransCode Therapeutics (NASDAQ: RNAZ) announced that its April 21 special meeting has been adjourned to May 2 at 9:30 a.m. Eastern after failing to meet the quorum requirement. Only 12.73% of eligible shares were represented, below the one-third threshold. The adjournment is intended to allow further proxy solicitation on two proposals: a reverse stock split authorization at a 1-for-10 to 1-for-40 ratio, and the potential for further adjournment if needed. Stockholders as of April 2 are encouraged to vote by May 1 at 11:59 p.m. Eastern through mail, phone, internet or during the virtual meeting. To view the full press…

Continue Reading

ThursdayApr 17, 2025 10:27 am

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) CEO Named EY Entrepreneur of the Year 2025 Finalist in Established Category 

Nutriband (NASDAQ: NTRB) CEO Gareth Sheridan has been named a finalist in the Established category of the 2025 EY Entrepreneur of the Year Awards. Sheridan is one of 27 Irish entrepreneurs recognized for their leadership and impact, with finalists selected from across 24 companies generating more than €1 billion in annual revenue.  Sheridan is being recognized for his role in transforming Nutriband from an early-stage startup into a U.S.-listed life sciences company focused on transdermal drug delivery and abuse-deterrent technologies. The company’s lead product, AVERSA™, is designed to prevent the misuse and abuse of opioid patches—addressing a critical gap in…

Continue Reading

ThursdayApr 17, 2025 9:25 am

BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Receives FDA Clearance to Begin Trials for CLD-201 in Solid Tumors

Calidi Biotherapeutics (NYSE American: CLDI) announced FDA clearance of its Investigational New Drug application for CLD-201, an allogeneic stem cell-based virotherapy targeting solid tumors including breast cancer, head and neck cancer, and soft tissue sarcoma. Backed by preclinical data showing immune system evasion and potent tumor-killing ability, CLD-201 is now cleared to enter clinical development. The therapy combines adipose-derived stem cells with oncolytic vaccinia virus, representing a novel immunotherapeutic approach for hard-to-treat cancers. To view the full press release, visit: https://ibn.fm/qhTKp About Calidi Biotherapeutics Calidi Biotherapeutics specializes in proprietary technology that empowers the immune system to combat cancer. The company’s novel…

Continue Reading